Author/Editor | Horvat-Ledinek, Alenka | |
Title | Primerjava uspešnosti zdravljenja bolnikov z multiplo sklerozo z interferonom beta-1b in glatiramer acetatom | |
Type | monografija | |
Place | Ljubljana | |
Publisher | Medicinska fakulteta | |
Publication year | 2001 | |
Volume | str. 36 | |
Language | slo | |
Abstract | Multiple sclerosis (MS) is an autoimmune disease, which most commonly affects young adults between age 20 and 40. Management of MS patients is divided into treatment of relapses, symptomatic treatment, prevention of new relapses, treatment of advanced forms of MS, and neurorehabilitation. Patients with relapsing-remittent MS (RRMS) are treated in Slovenija, according to and in compliance with international recommendation and criteria for imunomodulatory treatment with Interferon beta-1b (IFN beta-1b), Glatiramer acetat (GA), and Interferon beta-1a (IFN beta-1a). Trial results showed, that treatment with IFN beta-1b or GA reduces number of relapses, increases time to new relapse, and reduce the disease activity and the accumulation of disability. Only one trial that compared different imunomodulatory treatment results, was published until now. Retrospective trial was used to compare results of two years treatment of RRMS patients with IFN beta-1b and GA. Trial results showed, that therapy with IFN beta-1b or GA significantly reduced relapses. There was no significant difference in relapses between treated groups. Most patients treated with GA or IFN beta-1b did not show changes in EDSS, 13,3 % patients treated with GA showed worsening in EDSS, and no worsening was detected in patients on IFN beta-1b therapy. We only found differences in side effects. Patients treated with GA reported fewer side effects compared to patients treated with IFN beta-1b. Prior to decision which imunomodulatory treatment to use we must take into account not only known treatment results but also patient's daily activity and way of medicament application. | |
Descriptors | MULTIPLE SCLEROSIS INTERFERON-BETA ADJUVANTS, IMMUNOLOGIC DISABILITY EVALUATION RECURRENCE ALANINE LYSINE TYROSINE GLUTAMATES TREATMENT OUTCOME RETROSPECTIVE STUDIES |